Artelo Biosciences, Inc. last reported quarterly results on Jul 11, 2025, for Q2 FY2025 (the quarter ended Jun 30, 2025): diluted EPS of -$16.86. It usually reports 11–45 days after a quarter ends.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 11–45 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Jul 11, 2025
11 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
—
|
-3
-32.4%
|
-16.86
|
|
Jan 14, 2020
45 days after quarter end
|
—
ended Nov 30, 2019
|
—
|
—
|
—
|
|
Jul 15, 2019
45 days after quarter end
|
—
ended May 31, 2019
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ARTL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Solana Beach, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1621221
- Former names
- REACTIVE MEDICAL INC. (until Apr 17, 2017); KNIGHT KNOX DEVELOPMENT CORP. (until Feb 6, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.